NLRP3 Haploinsufficiency Drives Accelerated Inflammatory Aging in Mice via Compensatory NLRP1-NLRP3 Hybrid Inflammasome Formation

The NLRP3 inflammasome has been implicated in a wide range of human diseases, including cardiovascular, metabolic, neurodegenerative (e.g., Alzheimer's disease), and other age-related conditions, making it a key pharmacological target. While complete NLRP3 ablation prevents these diseases, it's not a viable therapeutic strategy. Drug development efforts focus on partial inhibition, yet the long-term effects of reduced NLRP3 expression, more representative of pharmacological approaches, remain poorly understood. This gap in understanding the consequences of partial NLRP3 inhibition is crucial for developing safe and effective anti-aging and anti-inflammatory therapies.

Researchers investigated the long-term effects of Nlrp3 haploinsufficiency in mice, a genetic model designed to mimic partial pharmacological inhibition. They observed Nlrp3 heterozygous mice alongside wild-type controls throughout their lifespan, specifically monitoring for signs of inflammatory aging. The primary endpoint was the assessment of age-related inflammatory markers and overall health span. Mechanistic studies were conducted to identify molecular interactions and pathways involved in the observed phenotypes, including evaluating the impact of general anti-inflammatory treatments and genetic inhibition of Nlrp1.

While Nlrp3 heterozygous mice showed no overt differences in early life, by 16 months of age, they exhibited clear signs of accelerated inflammatory aging. This phenotype was driven by a compensatory overexpression of NLRP1. Mechanistic investigations revealed a previously unidentified interaction between NLRP1 and NLRP3, leading to the formation of a novel hybrid inflammasome. This hybrid structure was responsible for driving NLRP1-mediated inflammatory overactivation when NLRP3 expression was reduced. Accordingly, general anti-inflammatory treatment provided notable but moderate improvement of the inflammatory phenotype.

Genetic inhibition of Nlrp1 more consistently reduced inflammation and extended the health span in Nlrp3 haploinsufficient mice, demonstrating superior efficacy compared to general anti-inflammatory approaches. These findings highlight a critical compensatory mechanism where reduced NLRP3 activity paradoxically exacerbates inflammation through NLRP1 upregulation and interaction.